OncologyOnline.net

Oncology Xagena

Cancer Drugs Fund ( CDF ) Panel has assessed the application was for single agent Pemetrexed ( Alimta ) to remain in the CDF as maintenance treatment for patients with locally advanced or metastatic ...


A new study has provided the first evidence that the mediator complex subunit 15 ( MED15 ) may play a crucial role in the pathophysiology of head and neck squamous cell carcinoma ( HNSCC ). MED15 ov ...


Axillary lymph node evaluation is performed frequently in women with ductal carcinoma in situ breast cancer, despite recommendations generally against such an assessment procedure in women with locali ...


In a study, researchers from Brigham and Women's Hospital ( BWH ) ( Boston, Massachusetts; USA ) have reported that breast surgery performed at or shortly after a diagnosis of low-grade ductal carcino ...


Pembrolizumab ( Keytruda ), an anti–PD-1 antibody, demonstrated antitumor activity and acceptable safety in patients with recurrent or metastatic PD-L1–positive urothelial cancer enrolled in the phase ...


A review, titled Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential, from researchers at The University of Texas MD Anderson Cancer Center published i ...


Findings investigating the use of Pembrolizumab ( Keytruda ), an anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer ( SCLC ), esophageal cancer and o ...


Cancer Drugs Fund ( CDF ) Panel has assessed the application for single agent Pemetrexed ( Alimta ) to remain in the CDF as 2nd line treatment for patients with non-squamous ( NS ) non-small cell lun ...


Immune checkpoint blockade may play a role in the treatment of metastatic urothelial cancer ( mUC ). However, the role of CTLA4 blockade, the impact of chemotherapy on immune cell populations, and the ...


Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to remain in the CDF list as 3rd line chemotherapy for patients with locally advanced or metastatic breast c ...


The application was for Regorafenib ( Stivarga ) to remain in the Cancer Drugs Fund ( CDF ) as treatment for patients with non-resectable or metastatic gastrointestinal stromal tumours ( GISTs ) who w ...


The LUME-Lung 1 trial has demonstrated a significant overall survival advantage for Nintedanib ( Vargatef ) plus Docetaxel ( Taxotere ) compared with placebo plus Docetaxel as second-line therapy for ...


A study has compared the incidence of vascular thromboembolic events ( VTEs ) in patients with metastatic or unresectable urothelial carcinoma ( UC ) who were treated with Gemcitabine and Carboplatin ...


Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung 3 and LUX-Lung 6, in patients with EGFR-mutant advanced non ...


The Cancer Drugs Fund ( CDF ) Panel has assessed the application for Eribulin ( Halaven ) to enter the CDF as an option for patients with locally advanced or metastatic HER-2 negative breast can ...